Thyrocare Technologies Ltd. News and Updates

Name: Latest research reports of Thyrocare Technologies Ltd. authored by Prabhudas Lilladhar and published by - Trendlyne research reports.
Item: Thyrocare Technologies Ltd.
Rating: 5
Author: Prabhudas Lilladhar

Keep track of all breaking news on Thyrocare Technologies Ltd. from all sources in a single place.

Load latest

Thyrocare Technologies Ltd.

23 Mar 2020

995.55

1.36%

Metropolis, Thyrocare say they will start tests for coronavirus from today

Business Standard

They would start collecting samples for testing from today. For starters, this would happen in Mumbai

Thyrocare Technologies Ltd. has gained 37.62% in the last 3 Months

Thyrocare Technologies Ltd.

12 Mar 2020

995.55

1.36%

Monthly Update - IPM growth not yet impacted by Covid-19

Buy: Thyrocare Technologies Ltd.

Prabhudas Lilladhar

IPM's MAT growth in Feb-20 was 9.7% as against 9.6% in Feb-19 and Jan-20. The growth was majorly contributed by price at 5.4%, volume at 1.9% and new product at 2.5%. In the last 12 months, contributors average growth towards price, volume and new products were 5.6%, 1.7% and 2.3% respectively. The growth attributed by new products and volume however has been on a declining trend in last 50 months, while price hike has been a key factor that has contributed to IPM's growth. With 70-75% intermediaries/API/KSM sourced from China, IPM hasn't been...

Thyrocare Technologies Ltd. has gained 37.62% in the last 3 Months

Thyrocare Technologies Ltd.

09 Mar 2020

995.55

1.36%

Sector Update - Re-emergence of regulatory threat to undermine earnings in near-term

Buy: Thyrocare Technologies Ltd.

Target

Prabhudas Lilladhar

FDA continues to maintain zero tolerance towards injectable units Indian generics ranked 2nd only after US for non-compliance issues of facilities by FDA. With the regulators focus towards approving more generics, Indian majors were short of compliance that led to missed opportunity of launching day-one generics and specialty products in CY19. With USFDA issued WL in CY19 to the Indian majors, the track record of achieving compliance in injectable plant were in shambles as work culture in sterile plant lacked training and integrity. The resolution might take longer than its...

Thyrocare Technologies Ltd. has gained 53.81% in the last 1 Year

Thyrocare Technologies Ltd.

04 Feb 2020

995.55

1.36%

Thyrocare Technologies hits 52-week high, surges 28% in two days

Business Standard

The company's normalized Ebitda grew 19 per cent year on year (YoY) at Rs 42.5 crore, while margins improved to 40 per cent compared with 37 per cent clocked in the previous year quarter

Thyrocare Technologi.. has an average target of 1000.00 from 1 broker.

Thyrocare Technologies Ltd.

22 Aug 2019

995.55

1.36%

Thyrocare Technologies Ltd: Revenues Enhanced by Volumes Growth

Buy: Thyrocare Technologies Ltd.

Karvy

Thyrocare Q1FY20 earnings came marginally higher than our estimates on account of healthy growth in samples collected

Thyrocare Technologies Ltd. has gained 41.89% in the last 1 Month

Thyrocare Technologies Ltd.

14 Aug 2019, 12:00AM

995.55

1.36%

Q1FY20 Result Update

Buy: Thyrocare Technologies Ltd.

Target

Prabhudas Lilladhar

diagnostic tests. Overall, Thyrocar increased 10% price for its sick care business in B2B segment while price of few tests in preventive care marginally reduced in Q1FY20. Management guided that the benefits of price rationalization in Aarogyam 1.1, 1.2 and 1.3 will be visible in FY20E. Hence, we expect better traction in volumes and growth in the remaining three quarters of FY20E. Management guided for increased focus on B-2-B business with higher incentives and revenues per franchisee as it focusses...

Thyrocare Technologies Ltd. has gained 37.62% in the last 3 Months

Thyrocare Technologies Ltd.

26 Apr 2019

995.55

1.36%

Thyrocare sees fresh insider trade purchases by promoters

Healthtech firm Thyrocare (which is in 12 stock screeners) has seen fresh insider trade purchases by its promoters. Promoters bought 82,900 Thyrocare shares in mid Feb, and 10,000 shares today (26 April). The company's share price is near its year low, and technicals are weak. Share price fell after the company showed YoY negative net profit growth and EPS growth in the December quarter.